Sjogren's Syndrome Epidemiology Summary
Sjögren's Disease Insights and Trends
- In 2025, the total number of diagnosed prevalent cases of Sjögren's disease in the 7MM was approximately 1 million. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases.
- According to epidemiological analysis, mild Sjögren’s disease cases in the US totaled to more than 500,000 cases in 2025, while moderate-to-severe cases accounted for more than 200,000 cases. The distribution highlights the substantial burden of moderate-to-severe disease within the diagnosed population, with the projected increase reflecting the evolving epidemiological profile of Sjögren’s disease in the US.
- A prolonged diagnostic journey remains a key epidemiological gap, with patients taking approximately 3 years to receive a Sjögren disease diagnosis, contributing to under-recognition of the disease and potentially limiting timely access to disease-directed management.
- Female patients and primary Sjögren disease represent the core diagnosed population, driven by the pronounced female predominance, with almost 90% of diagnosed patients being female, and the larger pool of patients with primary disease rather than Sjögren disease associated with other autoimmune conditions.
- The reported prevalence of Sjögren syndrome varies considerably across studies because estimates are influenced by differences in classification criteria, diagnostic approaches, population characteristics, and whether symptomatic or objectively confirmed disease is captured. The problem is further compounded by diagnostic delays and under-recognition, meaning that the clinically diagnosed population may represent only a portion of the underlying disease burden. Consequently, epidemiological estimates do not always translate directly into the diagnosed, specialist-managed, and ultimately treatable population relevant for commercial forecasting.
DelveInsight’s “Sjögren's Disease – Epidemiology Forecast – 2036” report delivers an in depth understanding of Sjögren's disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
- North America: The United States
- Europe: Germany, France, Italy, Spain and the United Kingdom
- Asia-Pacific: Japan
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2025 |
|
Geographies Covered |
|
|
Sjögren's Disease Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
Sjögren's Disease Understanding
Sjögren's Disease Overview and Diagnosis
Sjögren's disease, previously referred to as Sjögren's syndrome, is a chronic, systemic autoimmune disorder in which the body's immune system mistakenly targets its own exocrine glands, particularly the lacrimal (tear) glands and salivary glands. This immune-mediated attack results in lymphocytic infiltration and progressive damage to glandular tissue, impairing the glands' ability to produce adequate moisture.
The diagnosis of Sjögren’s disease remains challenging due to its heterogeneous presentation, overlapping autoimmune symptoms, and absence of a single definitive diagnostic test. Persistent sicca symptoms, anti-Ro/SSA antibody testing, Schirmer’s test, ocular staining, and salivary gland biopsy support disease identification under the 2016 ACR/EULAR classification criteria. Improved physician awareness and serological testing may enhance diagnosis, while seronegative and systemic cases continue to contribute to diagnostic delays.
Further details related to country-based variations are provided in the report…
Sjögren's Disease Epidemiology
Key Findings from Sjögren's Disease Epidemiological Analysis and Forecast
- In the US, total diagnosed prevalent cases of Sjögren’s disease were approximately 730,000 in 2025, supported by improved recognition of patients presenting with persistent sicca symptoms and the increasing adoption of serological testing, which facilitates disease identification and diagnosis.
- According to DelveInsight analysis, gender-specific diagnosed prevalent cases of Sjögren’s disease in the US in 2025 were predominantly female, accounting for approximately 650,000 cases, compared with around 75,000 male cases, reflecting the disease’s established female predominance.
- In 2025, Anti-Ro/SSA-positive cases represented the largest antibody-specific segment of diagnosed prevalent Sjögren’s disease cases across EU4 and the UK, totaling to approximately 410,000 cases.
Industry Experts and Physician Views for Sjögren's Disease
To keep up with Sjögren's disease patient trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on Sjögren's disease epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the John Hopkins University, Akiruno Medical Center, Grünenthal Foundation-University of Cadiz, Université Paris-Saclay, and Columbia University etc. were contacted.
|
Region |
Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) |
|
United States |
“Sjögren’s disease remains difficult to diagnose because its hallmark symptoms have multiple potential causes and may develop gradually. There is no single diagnostic test, requiring clinicians to integrate findings from multiple assessments; consequently, some patients may take years to receive a diagnosis.” |
|
Japan |
“Sjögren’s disease in Japan extends beyond isolated glandular manifestations, with a substantial proportion of patients having secondary disease and many patients with primary Sjögren’s presenting with extraglandular involvement. The Japanese epidemiological survey also highlighted the importance of screening for systemic organ involvement, reflecting the broader clinical burden of the disease.” |
Scope of the Report
- The report covers a segment of an executive summary, a descriptive overview of Sjögren's disease, explaining its causes, signs, symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Sjögren's Disease Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
FAQs
- What are the disease risks, burdens, and unmet needs of Sjögren's disease?
- What will be the growth opportunities across the 7MM concerning the patient population with Sjögren's disease?
- What is the Sjögren's disease prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What is the historical and forecasted Sjögren's disease patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on Sjögren's disease burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- Clear methodology, validated assumptions, and data-driven rationale to assess the Sjögren's disease epidemiology analysis and patient population trends.
